An embodiment provides a method for treating a body fluid of a patient, including: removing the body fluid from a patient; applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with an aging process targeted antigen (TA) in the body fluid to form an antibody-TA complex, wherein the antibody comprises a tag sensitive to an illumination; removing the antibody-antigen complex from the body fluid; and returning the body fluid to the patient. Other aspects are described and claimed.

An endovascular apparatus including a stabilizing element and a rod that may be detachably coupled to the stabilizing element. The rod may be elongated along a longitudinal axis. The rod may have at least one therapeutic agent thereon. The therapeutic agent may be an enzyme, an antibody, a biomarker, or a bioreceptor for neutralizing components of a bodily fluid of a patient. The rod may be inserted into the patient's body to place the therapeutic agent into fluid communication with the patient's bodily fluid. The rod may be formed from silicone and an outer surface of the rod may be etched prior to coating the rod with the therapeutic agent.

There is provided a sorbent for removing metabolic waste products from a dialysis liquid, the sorbent comprising a layer of immobilized uremic toxin-treating enzyme particles intermixed with cation exchange particles.

The present disclosure generally relates to a system for flowing a fluid, e.g., CSF, from a body of a patient for sampling and analysis. In some embodiments, the system can include a diagnostic module having one or more conduits for flowing fluid therethrough. The flow of the fluid through the valves can be regulated using a control board that changes an orientation of valves disposed in the conduits between a dead-end orientation and a flow-through orientation to sample and/or analyze the fluid from the system. In some embodiments, the fluid can be recirculated into the system through one or more of the valves, with sampling and recirculating occurring substantially simultaneously.

Provided are sorption materials and devices using the sorption materials, and methods of using the sorption materials and devices containing the sorption materials. In various examples, the sorption materials bind to various inflammation stimulating and/or mediating molecules, which are often associated with systemic infections and systemic inflammation associated with conditions such as, for example, sepsis.

Biological filters for removing target components from biological fluids such as removal of pathogenic cells from whole blood, are described. The filters may include a medium comprising an inert surface, with capture material disposed on the inert surface. The filter may be configured to selectively recognize, capture, and remove target cells such as pathogenic cells associated with a disease, such as an autoimmune disease or cancer. Devices, systems, apparatuses, computer readable media, and methods associated with biological filtering are also provided.

A process for removing Hg.sup.2+ toxins from bodily fluids is disclosed. The process involves contacting the bodily fluid with a titanium metallate ion exchanger to remove the metal toxins in the bodily fluid, including blood and gastrointestinal fluid. Alternatively, blood can be contacted with a dialysis solution which is then contacted with the ion exchanger. The titanium metallate ion exchangers are represented by the following empirical formula:
A.sub.mTiNb.sub.aSi.sub.xO.sub.y. A composition is provided with the combination of the titanium metallate ion exchanger and bodily fluids or dialysis solutions. Also, provided is an apparatus comprising a matrix and the titanium metallate ion exchanger.

A method of decreasing hypercoagulability and/or increasing plasma clotting time comprising removing red cell-derived particles (RCDP) from plasma.

The invention relates to a device for removing a gas from an aqueous liquid, particularly a blood liquid, comprising a first compartment permeated by the aqueous liquid during operation of the device; a second compartment permeated by a purging gas during operation of the device, the first compartment and the second compartment being separated from each other by a semipermeable membrane; and a third compartment permeated by a liquid proton donor during operation of device, said proton donor being an organic or inorganic acid, the first compartment and the third compartment being separated from each other by a membrane permeable to ions, and the membrane permeable to ions comprising at least one cation conductor.

The present invention relates to an apheresis column loaded with a solid support comprising a composition comprising at least one peptide selected from the group consisting of: —the αI7I-I85cit peptide of amino acid sequence VDIDIKIX.sub.1SCX.sub.2GSCS (SEQ ID NO: 8) wherein X.sub.1 and X.sub.2 each represent a citmllyl residue, —the α62I-635Cit peptide of amino acid sequence X1GHAKSX2PVX3GIHTS (SEQ ID NO: 12) wherein X1, X2 and X3 each represent a citmllyl residue—the P60-74cit-NH2 peptide of amino acid sequence X1PAPPPISGGGYX2AX3 (SEQ ID NO: 15) wherein X1 and X2 each represent a citmllyl residue and X3 represents a citmllyl derivative with a carboxamide group and—the peptide, referred to as the Ac-a36-50crt peptide, having the amino acid sequence GPX1VVEX2HQSACKDS (SEQ ID NO: 6) wherein the residue G at the N-terminal is acetylated and wherein X1 and X2 each represent a citmllyl residue and/or the a36-50cit peptide of amino acid sequence GPX1VVEX2HQSACKDS (SEQ ID NO: 5) wherein X.sub.1 and X.sub.2 each represent a citmllyl residue.